GLP-1 Receptor Agonist Exposure Linked to Neovascular AMD in Patients With Diabetes
FRIDAY, June 6, 2025 — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular degeneration (nAMD) development, according to a…
EMA considers serious eye condition a ‘very rare’ side effect of semaglutide
The European Medicines Agency said Friday that the product information for Novo Nordisk’s Ozempic and Wegovy should be updated to list a serious eye condition as a “very rare” side effect. A
GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns
(MedPage Today) — A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. Following a review of all available data, the…
Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide
Publication date: Available online 6 June 2025 Source: Bioorganic & Medicinal Chemistry Author(s): Chengcheng Wang, Jinhua Zhang, Yuanzhen Dong, Jun Xu, Jianguang Lu, Chunyong Ding, Zhengyan Cai, Jun Feng